Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,405,866
  • Shares Outstanding, K 308,534
  • Annual Sales, $ 528,300 K
  • Annual Income, $ -56,110 K
  • EBIT $ 40 M
  • EBITDA $ 51 M
  • 60-Month Beta 0.42
  • Price/Sales 7.34
  • Price/Cash Flow N/A
  • Price/Book 19.12

Options Overview Details

View History
  • Implied Volatility 48.54% (+9.41%)
  • Historical Volatility 77.32%
  • IV Percentile 16%
  • IV Rank 12.54%
  • IV High 290.42% on 09/25/25
  • IV Low 13.88% on 12/19/25
  • Expected Move (DTE 3) 0.26 (1.85%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 111
  • Volume Avg (30-Day) 2,296
  • Put/Call OI Ratio 1.03
  • Today's Open Interest 35,679
  • Open Int (30-Day) 33,437
  • Expected Range 14.02 to 14.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.07
  • Number of Estimates 3
  • High Estimate 0.08
  • Low Estimate 0.04
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.50 +36.00%
on 12/15/25
14.36 -0.56%
on 12/19/25
+3.73 (+35.36%)
since 12/12/25
3-Month
7.87 +81.45%
on 10/17/25
14.36 -0.56%
on 12/19/25
+5.98 (+72.05%)
since 10/10/25
52-Week
5.51 +159.17%
on 06/25/25
14.36 -0.56%
on 12/19/25
+5.26 (+58.31%)
since 01/10/25

Most Recent Stories

More News
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.

FOLD : 14.28 (unch)
REVG : 68.27 (+1.80%)
THS : 24.02 (+0.17%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--EKSO, FOLD, CWAN, and JHG

NEW YORK , Jan. 7, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

FOLD : 14.28 (unch)
EKSO : 8.78 (+10.72%)
JHG : 47.95 (+0.40%)
CWAN : 24.09 (-0.17%)
Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

FOLD : 14.28 (unch)
DVAX : 15.68 (+1.75%)
DBRG : 15.36 (unch)
Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.

FOLD : 14.28 (unch)
EKSO : 8.78 (+10.72%)
CFLT : 30.43 (+0.23%)
WBD : 28.40 (-1.68%)
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics...

FOLD : 14.28 (unch)
BMRN : 57.71 (-2.10%)
Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

FOLD : 14.28 (unch)
DHIL : 170.70 (+0.29%)
KPLT : 7.02 (-2.36%)
A $4.8 Billion Reason to Buy BioMarin Stock Today

BioMarin stock soars as the biotech firm announces a $4.8 billion acquisition of Amicus Therapeutics. The transaction could push BMRN shares even higher in 2026.

FOLD : 14.28 (unch)
BMRN : 57.71 (-2.10%)
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

FOLD : 14.28 (unch)
FLD : 2.48 (+0.81%)
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

FOLD : 14.28 (unch)
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin to Gain Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth...

FOLD : 14.28 (unch)
BMRN : 57.71 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is...

See More

Key Turning Points

3rd Resistance Point 14.33
2nd Resistance Point 14.31
1st Resistance Point 14.30
Last Price 14.28
1st Support Level 14.27
2nd Support Level 14.25
3rd Support Level 14.24

See More

52-Week High 14.36
Last Price 14.28
Fibonacci 61.8% 10.98
Fibonacci 50% 9.93
Fibonacci 38.2% 8.89
52-Week Low 5.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar